Core Viewpoint - The company has approved the use of idle raised funds and self-owned funds for cash management and entrusted financial management, ensuring that the normal operation of investment projects and fund safety are prioritized. Group 1: Fund Management Approval - The company convened the 10th meeting of the 8th Board of Directors and the 10th meeting of the 8th Supervisory Board on January 20, 2025, to approve the proposal for cash management using idle raised funds and self-owned funds, with a limit of up to RMB 100 million for raised funds and RMB 150 million for self-owned funds [1][2]. Group 2: Redemption of Financial Products - The company and its wholly-owned subsidiaries have redeemed all principal and income from cash management products and entrusted financial management as of the announcement date [1][7]. Group 3: Approval Process - The proposal for cash management has been approved by both the Board of Directors and the Supervisory Board, with clear consent from the supervisory board and the sponsor institution [2]. Group 4: Financial Impact - As of the announcement date, the company has not exceeded the authorized limit for cash management using idle raised funds and self-owned funds, with a balance of RMB 0 for both categories [7]. Group 5: Documentation of Financial Products - The company has provided documentation for various redeemed financial products, including structured deposits and asset management plans, indicating a diversified approach to cash management [8][9].
吉林省西点药业科技发展股份有限公司 关于使用闲置募集资金及自有资金进行现金管理和委托理财到期赎回的公告